Market Cap
$2.9B
PGEN
PRECIGEN, INC.
$8.26 ▲ +0.61%
Prev close $8.21Market cap$2.9B
ConsensusBuy
12-mo target$13.65 (+65.2%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)26 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PGEN right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (78%)
Inst. Holders
50 funds
Inst. Value
$481.2M
Inst. Activity
26 buys / 9 sells
Insider Activity
$24.7K buy / $8.0M sell
Insider Net $
-$7.9M
Social Sentiment
63° Warm
SEC Reports
12
Price chart 30d +17.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 short_volume
Short Volume: PGEN — 71.5% short (1.3M / 1.8M)
Short: 1,314,738 | Exempt: 300 | TRF Vol: 1,838,149 | Short Ratio: 71.5% | Off-exchange volume (dark
Sep 23, 2026 Insider
Thomasian Harry Jr. acquired via exercise 42,918 shares
Chief Financial Officer @ $2.33 ($100.0K)
Sep 23, 2026 Insider
Thomasian Harry Jr. acquired via exercise 2 shares
Chief Financial Officer @ $0.9600 ($1.92)
Sep 23, 2026 Insider
Aug 29, 2026 SEC Thomasian Harry Jr. acquired via exercise 10,744 shares
Chief Financial Officer @ $4.72 ($50.7K)
A mixed insider cluster at Precigen shows a director selling $1.38M in open-market shares and the CCO selling $594K post
CLUSTER — Impact 3/10
Director Jeffrey Kindler filed a Form 144 to sell 185,000 shares of Precigen (PGEN) at an estimated aggregate value of $
144 — Impact 3/10
Precigen insiders show a mixed cluster: Director Nancy Agee made a small $25K open-market buy, while COO Rutul Shah sold
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
3,469,628 shares ($19.8M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
78% rate it Buy or better · 9 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | B. Riley Securities | INITIATE | Buy | 54% |
| Aug 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 14, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| May 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Aug 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jul 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Price targets
Where 3 covering analysts think PGEN trades over the next 12 months.
$13.65 +65.2% upside Strong Buy
Current$8.27 Low$11.00 Median$12.00 High$17.95 3 analysts
$11.00$17.95
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment mood +7.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
63°
Warm
BearishNeutralBullish
Recent posts
Biotech breakout $PGEN Precigen
▲ 1 · 💬 3· ⚡ 0.5
Free money by Wednesday 5th of August - $PGEN
▲ 1 · 💬 7· ⚡ 0.5
Precigen stock jumps after Q1 2026 beat (PGEN:NASDAQ)
▲ 1 · 💬 0· ⚡ 0.5
Is PGEN worth the price?
▲ 1 · 💬 1· ⚡ 0.5
Papzimeos from PGEN, $115,000 per vial and $460,000 for the full course, boosts Q1 earnings
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 9 neutral · avg impact 3.3/10.
NEUTRALCLUSTER3/10
A mixed insider cluster at Precigen shows a director selling $1.38M in open-market shares and the CC
Aug 29, 2026
NEUTRAL1443/10
Director Jeffrey Kindler filed a Form 144 to sell 185,000 shares of Precigen (PGEN) at an estimated
Aug 26, 2026
BEARISHCLUSTER4/10
Precigen insiders show a mixed cluster: Director Nancy Agee made a small $25K open-market buy, while
Aug 26, 2026
NEUTRALCLUSTER2/10
Precigen (PGEN) insiders showed mixed activity in a 7-day cluster: Director Nancy Agee made a small
Aug 25, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
short_volume
Short Volume: PGEN — 71.5% short (1.3M / 1.8M)
Short: 1,314,738 | Exempt: 300 | TRF Vol: 1,838,149 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
other
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept.
Sep 15, 2026
short_volume
Short Volume: PGEN — 65.1% short (0.6M / 0.9M)
Short: 615,134 | Exempt: 1,071 | TRF Vol: 945,393 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
Aug 28, 2026
ftd
FTD: PGEN — 113,406 shares ($0.8M) failed to deliver
Settlement: 20260828, Price: $7.19, FTD Value: $815,389.14, PRECIGEN INC COM STK (VA)
Aug 5, 2026
short_volume
Short Volume: PGEN — 59.2% short (3.7M / 6.2M)
Short: 3,679,937 | Exempt: 5,337 | TRF Vol: 6,216,677 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.08 | $0.05–$0.14 | 107.7% | +3.7% | — | $0.1B | 4 |
| Next Q | $0.11 | $0.06–$0.21 | 1199.2% | +0.0% | — | $0.1B | 4 |
| Current FY | $0.22 | $0.14–$0.38 | 116.3% | +1.1% | — | $0.2B | 4 |
| Next FY | $0.63 | $0.29–$1.32 | 184.8% | -7.0% | 2↑ 0↓ | $0.4B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.081 | — |
| 7d ago | $0.078 | +0.003 |
| 30d ago | $0.078 | +0.003 |
| 60d ago | $-0.003 | +0.085 |
| 90d ago | $-0.003 | +0.085 |
Institutional ownership
Which big funds own PGEN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $481.2M total value (84,382,948 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 26 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 17,146,921 | $97.7M | 20.3% | — |
| STATE STREET CORP | 12,002,465 | $68.4M | 14.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,906,160 | $45.1M | 9.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 5,019,028 | $28.6M | 5.9% | — |
| MORGAN STANLEY | 3,469,628 | $19.8M | 4.1% | ADD +43.7% |
| GOLDMAN SACHS GROUP INC | 3,406,456 | $19.4M | 4.0% | — |
| FMR LLC | 2,570,183 | $14.7M | 3.0% | ADD +28.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,211,172 | $12.6M | 2.6% | — |
| FIRST TRUST ADVISORS LP | 2,014,659 | $11.5M | 2.4% | NEW |
| BANK OF AMERICA CORP /DE/ | 1,848,414 | $10.5M | 2.2% | ADD +25.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 2,414,322 | 3,469,628 | +43.7% | $19.8M |
| FMR LLC | ADD | 1,998,596 | 2,570,183 | +28.6% | $14.7M |
| FIRST TRUST ADVISORS LP | NEW | — | 2,014,659 | — | $11.5M |
| BANK OF AMERICA CORP /DE/ | ADD | 1,471,279 | 1,848,414 | +25.6% | $10.5M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 395,695 | 1,788,235 | +351.9% | $10.2M |
| Point72 Asset Management, L.P. | NEAR_EXIT | 6,644,361 | 1,266,679 | -80.9% | $7.2M |
| BARCLAYS PLC | ADD | 491,696 | 931,368 | +89.4% | $5.3M |
| Caption Management, LLC | DOUBLED | 306,616 | 900,000 | +193.5% | $5.1M |
| CITADEL ADVISORS LLC | TRIM | 2,702,383 | 820,389 | -69.6% | $4.7M |
| CITIGROUP INC | ADD | 381,365 | 724,887 | +90.1% | $4.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 50 transactions. Net -$7.9M — $24.7K bought, $8.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Thomasian Harry Jr. | Chief Financial Officer | EXERCISE | 42,918 | $2.33 | $100.0K |
| Sep 23, 2026 | Thomasian Harry Jr. | Chief Financial Officer | EXERCISE | 2 | $0.9600 | $1.92 |
| Sep 23, 2026 | Thomasian Harry Jr. | Chief Financial Officer | EXERCISE | 10,744 | $4.72 | $50.7K |
| Sep 23, 2026 | Thomasian Harry Jr. | Chief Financial Officer | EXERCISE | 1 | $1.21 | $1.21 |
| Aug 26, 2026 | KINDLER JEFFREY B | Director | SELL | 185,000 | $7.44 | $1.4M |
| Aug 25, 2026 | Tennant Phil | Chief Commercial Officer | EXERCISE | 79,166 | $1.61 | $127.5K |
| Aug 25, 2026 | Shah Rutul R | Chief Operating Officer | SELL | 15,342 | $7.50 | $115.1K |
| Aug 25, 2026 | Shah Rutul R | Chief Operating Officer | EXERCISE | 15,342 | $2.33 | $35.7K |
| Aug 25, 2026 | Tennant Phil | Chief Commercial Officer | SELL | 79,166 | $7.50 | $593.7K |
| Aug 23, 2026 | Tennant Phil | Chief Commercial Officer | EXERCISE | 5,208 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PGEN.
Shares short
42,278,237
Settlement Sep 15, 2026
Change vs prior
+0.2%
Semi-monthly cycle
Days to cover
16.3
At avg daily volume
Of shares outstanding
≈11.8%
Estimate — not % of float
All PGEN filing & press-release reports (12)
- CLUSTER reportAug 29, 2026
- 144 reportAug 26, 2026
- CLUSTER reportAug 26, 2026
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 3, 2026
- CLUSTER reportJul 2, 2026
- 8-K reportJun 25, 2026
- CLUSTER reportJun 1, 2026
- CLUSTER reportJun 1, 2026
- 8-K reportMay 13, 2026
- 144 reportMar 30, 2026